Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

Launched by UNIVERSITY OF PITTSBURGH · Sep 27, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a supplement called MitoQ on patients with sickle cell disease (SCD). MitoQ acts as an antioxidant, which means it helps protect cells from damage caused by harmful substances in the body. The main goal of the study is to see if MitoQ can improve how platelets function in people with SCD, which is important because platelets help with blood clotting and overall health.

To participate in this trial, you need to be African American, at least 18 years old, and have sickle cell anemia. Healthy African American individuals can also join as a comparison group. However, if you are pregnant, have high blood pressure, or certain other medical conditions, you may not be eligible. Participants will take MitoQ and be monitored for its effects. This study is currently looking for volunteers, and it aims to provide new insights into potential treatments for sickle cell disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects
• • African American
• • Patients with sickle cell anemia
• • 18 years old or older
• • Control
• • African American healthy controls
• • 18 years of age or older
• Exclusion Criteria:
• • 1. Pregnancy,
• • 2. Known hypertension,
• • 3. Hemodialysis and active obstructive sleep apnea requiring treatment.
• • 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.